Last reviewed · How we verify

NCT02756247

A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma

Completed Phase 1 Last updated 10 October 2022
What this trial tests

Phase 1 trial testing Buparlisib in Lymphoma in 37 participants. Completed in 6 October 2022.

Timeline
9 May 2016
Primary endpoint
6 October 2022
6 October 2022

Quick facts

Lead sponsorMemorial Sloan Kettering Cancer Center
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment37
Start date9 May 2016
Primary completion6 October 2022
Estimated completion6 October 2022
Sites6 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Memorial Sloan Kettering Cancer Center — full company profile →

Who can join

18 and older, any sex, with Lymphoma or Mantle Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to find out if the combination of buparlisib and ibrutinib will lead to better treatment results in patients with relapsed or refractory Follicular lymphoma, (FL) Mantle cell lymphoma (MCL) or Diffuse Large B-cell lymphoma (DLBCL). The investigators are using buparlisib and ibrutinib because both drugs seem to block different proteins that allow cancer cells to keep growing. Blocking these proteins may help by making the cancer cells undergo cell death, which will stop uncontrolled tumor growth.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Targeting PI3K in cancer: mechanisms and advances in clinical trials.
    Yang J, Nie J, Ma X, Wei Y, et al · · 2019 · cited 1142× · PMID 30782187 · DOI 10.1186/s12943-019-0954-x
  2. PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects.
    Mishra R, Patel H, Alanazi S, Kilroy MK, et al · · 2021 · cited 207× · PMID 33801659 · DOI 10.3390/ijms22073464
  3. New agents and regimens for diffuse large B cell lymphoma.
    Wang L, Li LR, Young KH. · · 2020 · cited 109× · PMID 33317571 · DOI 10.1186/s13045-020-01011-z
  4. Buparlisib is a brain penetrable pan-PI3K inhibitor.
    de Gooijer MC, Zhang P, Buil LCM, Çitirikkaya CH, et al · · 2018 · cited 56× · PMID 30018387 · DOI 10.1038/s41598-018-29062-w
  5. Small-molecule agents for cancer immunotherapy.
    Wang F, Fu K, Wang Y, Pan C, et al · · 2024 · cited 41× · PMID 38486980 · DOI 10.1016/j.apsb.2023.12.010
  6. Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets.
    Miao Y, Medeiros LJ, Xu-Monette ZY, Li J, et al · · 2019 · cited 39× · PMID 30881917 · DOI 10.3389/fonc.2019.00107
  7. Immunometabolism in cancer: basic mechanisms and new targeting strategy.
    Su R, Shao Y, Huang M, Liu D, et al · · 2024 · cited 28× · PMID 38755125 · DOI 10.1038/s41420-024-02006-2
  8. Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Harris LJ, Patel K, Martin M. · · 2020 · cited 27× · PMID 33202794 · DOI 10.3390/ijms21228553

Verify or expand the search:

Other trials of Buparlisib

Trials testing the same drug.

Other recruiting trials for Lymphoma

Currently open trials in the same condition.

Other Memorial Sloan Kettering Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02756247.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing